Indegene (INDGN) — Financial Results

Investor Takeaways

Settlement framework allows up to USD 4.72 million in potential payments for TCPA class-action lawsuit involving 18,851 fax numbers from 2020

Court approval required before settlement becomes effective

No admission of liability confirmed by company

⚠️ Material litigation risk resolved without immediate financial impact on current financials

Overall Tone: Neutral based on the numbers only.

Key Financial Highlights

Metric	Value	YoY Change
Revenue	Not available	Not available
Net Profit	Not available	Not available
EBITDA	Not available	Not available
EPS	[amount context mismatch]	Not available
OPM	18.3%	Not available

What Changed

The filing discloses final settlement terms for Indegene Inc.'s TCPA class-action lawsuit covering 18,851 fax numbers from 2020. The settlement framework permits up to USD 4.72 million in payments at USD 250 per approved claim, subject to valid claim volumes and court approval. This resolves material litigation risk without affecting current financials, as emphasized in the filing. The company has been authorized to proceed with execution pending judicial approval, with no admission of liability.

Peer Comparison

Company	P/E	ROE	ROCE	Market Cap (₹ Cr)
Indegene Limited	31.3	Not available	Not available	12,432.92
Sun Pharmaceutical Industries Limited	41.28	15.11%	20.34%	4,50,643.09
Divi's Laboratories Limited	72.41	16.56%	22.09%	1,79,470.03
Torrent Pharmaceuticals Limited	80.06	Not available	Not available	1,49,108.91

Indegene's P/E ratio of 31.3 is lower than Divi's Laboratories (72.41) and Torrent Pharmaceuticals (80.06), but higher than Sun Pharmaceutical (41.28).

Risks & Concerns

No specific risks identified in this filing beyond the resolved litigation matter

⚠️ Settlement depends on court approval and valid claim volumes

Actual financial impact remains contingent on claim validation

Quarterly Trend

Quarter	Revenue (₹ Cr)	Net Profit (₹ Cr)	OPM%
Q3FY25	720.4	109.7	18.3%
Q2FY25	686.8	91.7	18.36%
Q1FY25	676.5	87.7	19.05%
Q4FY24	673	94.8	20.61%

📄 View Original Announcement (PDF)

📊 Stock Analysis — INDGN ✨ Ask AI About This

About Indegene Limited (INDGN)

Healthcare · Healthcare · Listed on NSE

Market Cap: ₹14,597.01 Cr P/E: 36.3 ROE: 12.8% ROCE: 17.4% Div Yield: 0.37%

View full INDGN stock details →

📡 Get AI alerts when INDGN files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track INDGN — Free

💡 Ask AI about this filing

"What's the expected timeline for court approval?" "How many claims might be filed under the settlement?" "What's the potential range of actual settlement costs?"

Ask AI Free →

📊 More INDGN filings

See all INDGN filings →

🔥 Also filed on 19 August 2026

GOCOLORS Go Fashion (India) Limited Annual Report OIL Oil India Limited Corporate Action GLAXO GlaxoSmithKline Pharmaceuticals Limited Financial Results TIL TIL Limited Financial Results SETUINFRA Setubandhan Infrastructure Limited Financial Results ASALCBR Associated Alcohols & Breweries Ltd. Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when INDGN files new disclosures

Track INDGN filings, board meetings, and corporate actions. Free email alerts at 5 PM.